DrugPatentWatch
Depends
Confidence: Low
Buy only if you run portfolio, BD, or litigation strategy inside a pharma company and need patent-cliff forecasting; the free trial makes testing cheap.
New check
Comparison
DrugPatentWatch and Cortellis both land on Depends.
Buy only if you run portfolio, BD, or litigation strategy inside a pharma company and need patent-cliff forecasting; the free trial makes testing cheap.
Buy only if you are a pharma or biotech org whose R&D, regulatory, or BD teams need deep drug, deal, and regulatory data and can absorb a six-figure annual contract.
| Compare | ||
|---|---|---|
| Verdict | Depends | Depends |
| Best for | Pharma portfolio and lifecycle strategy teams | Pharma competitive intelligence and BD teams |
| Who it's not for | Hospitals, clinics, pharmacies . clinical needs, not market intelligence | Startups and small biotechs without six-figure data budgets |
| Privacy | No known public vulnerabilities found in the sources reviewed.² | Backed by Clarivate's trust center, but a SAML vulnerability is referenced in reviews and itself has no security page. |
| Support quality | No support evidence in sources | No support-quality evidence found |
| Public sentiment | No independent user reviews surfaced in the sources reviewed; coverage is vendor-authored content and trade news.⁵ | Reddit users rate Cortellis data best-in-class among pharma intel databases but repeatedly gripe about the price.13 |
| Biggest gotcha | Expect an enterprise-style sales process; published pricing is absent, so budget negotiation time.¹ | Quote-based pricing with no list price; expect lengthy procurement and negotiation14 |